Directeur de recherche Inserm
Directeur de l’ART “Ultrasons biomédicaux”
Tel : 01 40 79 51 67
Research is now becoming more and more interdisciplinary in order to compete and to generate real progress. This is the philosophy behind the first accelerator of technological research established by Inserm in the field of biomedical ultrasound. To achieve this goal, physicists, biologists, clinicians and engineers capable of taking the technological constraints into account, are translating the concept into usable and transferable tools for other researchers and physicists that will be working at the same site.
Innovations stemming from the “Biomedical Ultrasound” ART will be designed so that they can be transferred to other Inserm laboratories or hospitals within the three major areas of medical research — cancer, cardiovascular diseases and neuroscience.
Researchers hope to offer in the near future:
– Instruments capable of treating heart failure without surgery;
– Miniature imaging systems for brain activity;
– Brain-computer interface for treating major neurological disorders such as depression;
– Portable smart sensors capable of measuring and storing a variety of functional parameters;
– Ultrasound imaging systems for the remote delivery of drugs to tumours under perfectly controlled conditions, or to activate these drugs remotely in the targeted area only.
A group of high-level Inserm engineers will continue to accompany the physicists from the “Wave Physics for Medicine” team (Inserm/CNRS/ESPCI Paris) led by Mickael Tanter, in order to further the development of new technology emerging from the laboratory. These engineers will also be in charge of making this technology simple to use, consistent with medical standards, training new users and constantly improving the performance of these tools.
“In order to make major medical advances, it is now becoming more essential to provide innovative technology shortly after its creation. Many interdisciplinary partnerships already exist between hospitals, research centres and our “Wave Physics for Medicine” team. Our laboratory has already been the source of major industrial success, such as SuperSonic Imagine (Aixplorer ®) and Echosens (Fibroscan®), two devices now used by medical teams to reduce liver biopsies for cases of hepatic fibrosis and for cases of suspected cancer tumours. Many other discoveries are currently being developed and our collaborations will be helped and strengthened by ART staff dedicated to deploying technologies to partners. The “Biomedical Ultrasound” ART shall act as a genuine accelerator for new discoveries in medicine” says Mickael Tanter.
The ART will be housed on the new premises at ESPCI Paris (City of Paris Advanced School of Industrial Physics and Chemistry) located in the heart of Paris.
Created in 1964, the French National Health and Medical Research Institute (Inserm) is a public scientific and technical research establishment, under the joint supervision of the French Ministry of Education, Higher Education and Research and the French Ministry of Social Affairs, Health and Women’s Rights. Inserm is the only French public body dedicated to biological and medical research and human health, and occupies a position along the entire pathway from the laboratory to the patient’s bedside. Its researchers study all diseases from the most common to the most rare.
With a budget of €998 million in 2015, Inserm supports nearly 300 laboratories distributed throughout France. Together the teams comprise nearly 15,000 researchers, engineers, technicians, managers, clinician-researchers, post-doctoral fellows, etc.
About ESPCI Paris
ESPCI Paris is unique place at the centre of Montagne Sainte-Geneviève in the fifth arrondissement, which combines education, research and innovation. The school is characterised by its high-level scientific training and interdisciplinary approach, strongly backed by research excellence, combining fundamental science and openness towards applications and innovation. Housing 9 joint research units (UMR), the school is recognised worldwide for research excellence in fundamental and applied science and drives innovation within the industry. It was founded as an engineering school in the City of Paris in 1882. A paragon of French education, the school has 6 Nobel Prize laureates since its inception. The “Wave Physics for Medicine” team from the “Waves and Imaging” unit at Institut Langevin is based at the school.
The French Plan for Genomic Medicine 2025 was presented to Prime Minister Manuel Valls by Yves Lévy, President of the National Alliance for Life Sciences and Health (Aviesan) and CEO of Inserm, on 22 June 2016. ...
Inserm and the Coalition for Epidemic Preparedness Innovations (CEPI) are holding a large conference entitled "Vaccines Against Emerging Infections – a Global Insurance" on 21 and 22 February 2017. It is especially aimed at emphasising the urgent need for action and the ...